Literature DB >> 25459942

Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer's disease by direct infusion mass spectrometry.

Raúl González-Domínguez1, Tamara García-Barrera2, Javier Vitorica3, José Luis Gómez-Ariza4.   

Abstract

The identification of pathological mechanisms underlying to Alzheimer's disease is of great importance for the discovery of potential markers for diagnosis and disease monitoring. In this study, we investigated regional metabolic alterations in brain from the APP/PS1 mice, a transgenic model that reproduces well some of the neuropathological and cognitive deficits observed in human Alzheimer's disease. For this purpose, hippocampus, cortex, cerebellum and olfactory bulbs were analyzed using a high-throughput metabolomic approach based on direct infusion mass spectrometry. Metabolic fingerprints showed significant differences between transgenic and wild-type mice in all brain tissues, being hippocampus and cortex the most affected regions. Alterations in numerous metabolites were detected including phospholipids, fatty acids, purine and pyrimidine metabolites, acylcarnitines, sterols and amino acids, among others. Furthermore, metabolic pathway analysis revealed important alterations in homeostasis of lipids, energy management, and metabolism of amino acids and nucleotides. Therefore, these findings demonstrate the potential of metabolomic screening and the use of transgenic models for understanding pathogenesis of Alzheimer's disease.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APP/PS1 mice; Alzheimer's disease; Brain regions; Direct infusion mass spectrometry; Metabolomics

Mesh:

Substances:

Year:  2014        PMID: 25459942     DOI: 10.1016/j.jpba.2014.10.009

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  23 in total

1.  Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimer's Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Agonist.

Authors:  Kai Lun Chang; Ling Rong Wong; Hai Ning Pee; Shili Yang; Paul Chi-Lui Ho
Journal:  Mol Neurobiol       Date:  2019-04-23       Impact factor: 5.590

2.  Simultaneous Multiplexed Imaging of Biomolecules in Transgenic Mouse Brain Tissues Using Mass Spectrometry Imaging: A Multi-omic Approach.

Authors:  Minh-Uyen Thi Le; Hyun Kyong Shon; Hong-Phuong Nguyen; Chul-Ho Lee; Kyoung-Shim Kim; Hee-Kyung Na; Tae Geol Lee
Journal:  Anal Chem       Date:  2022-06-13       Impact factor: 8.008

3.  Amelioration of cognitive impairments in APPswe/PS1dE9 mice is associated with metabolites alteration induced by total salvianolic acid.

Authors:  Li Shen; Bing Han; Yuan Geng; Jinhua Wang; Zhengmin Wang; Mingwei Wang
Journal:  PLoS One       Date:  2017-03-30       Impact factor: 3.240

4.  Tocotrienol-Rich Fraction of Palm Oil Improves Behavioral Impairments and Regulates Metabolic Pathways in AβPP/PS1 Mice.

Authors:  Lina Wati Durani; Hamizah Shahirah Hamezah; Nor Faeizah Ibrahim; Daijiro Yanagisawa; Muhammad Luqman Nasaruddin; Masaki Mori; Kamalrul Azlan Azizan; Hanafi Ahmad Damanhuri; Suzana Makpol; Wan Zurinah Wan Ngah; Ikuo Tooyama
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Metabolic basis of neuronal vulnerability to ischemia; an in vivo untargeted metabolomics approach.

Authors:  Sherif Rashad; Daisuke Saigusa; Takahiro Yamazaki; Yotaro Matsumoto; Yoshihisa Tomioka; Ritsumi Saito; Akira Uruno; Kuniyasu Niizuma; Masayuki Yamamoto; Teiji Tominaga
Journal:  Sci Rep       Date:  2020-04-16       Impact factor: 4.379

6.  CircRNA-ceRNA Network Revealing the Potential Regulatory Roles of CircRNA in Alzheimer's Disease Involved the cGMP-PKG Signal Pathway.

Authors:  Yuan Zhang; Lili Qian; Yingying Liu; Ying Liu; Wanpeng Yu; Yanfang Zhao
Journal:  Front Mol Neurosci       Date:  2021-05-21       Impact factor: 5.639

7.  Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia.

Authors:  Adriana Cristofano; Nadia Sapere; Giancarlo La Marca; Antonella Angiolillo; Michela Vitale; Graziamaria Corbi; Giovanni Scapagnini; Mariano Intrieri; Claudio Russo; Gaetano Corso; Alfonso Di Costanzo
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

8.  A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease.

Authors:  Naijing Li; Ying Liu; Wei Li; Ling Zhou; Qing Li; Xueqing Wang; Ping He
Journal:  J Ginseng Res       Date:  2015-04-30       Impact factor: 6.060

Review 9.  Application of Metabolomics in Alzheimer's Disease.

Authors:  Jordan Maximillian Wilkins; Eugenia Trushina
Journal:  Front Neurol       Date:  2018-01-12       Impact factor: 4.003

10.  Divergence in the metabolome between natural aging and Alzheimer's disease.

Authors:  Holly C Hunsberger; Bennett P Greenwood; Vladimir Tolstikov; Niven R Narain; Michael A Kiebish; Christine Ann Denny
Journal:  Sci Rep       Date:  2020-07-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.